GET DAILY SIGNALSRepligen (RGEN) Delivers Record Q3 Revenue Up +10.9% and Raises Full-Year Guidance
Key Takeaways
- Repligen posted record third-quarter revenue of $209.3 million, up 10.9% year over year and slightly ahead of the roughly $207 million consensus estimate.
- Adjusted earnings per share (EPS) of $0.53 beat analyst expectations of $0.46, while organic revenue growth reached 12.5%.
- On a GAAP basis, the company reported a net loss of $38.4 million, or $0.68 per share, driven by a $41 million intangible asset impairment charge.
- Management raised full-year 2026 guidance, with revenue now expected between $844 million and $852 million and adjusted EPS near $2.07 at the midpoint.
- Franchise performance was mixed: chromatography grew more than 50%, proteins more than 40%, and analytics 20%, while filtration declined 11%.
Earnings Context and Why It Matters
Repligen is a leading supplier of bioprocessing technologies used to manufacture biological drugs, serving biopharmaceutical developers and contract development and manufacturing organizations (CDMOs). Its results are closely watched as a barometer of demand across the broader bioprocessing supply chain, which has been recovering from a post-pandemic inventory correction. A record revenue quarter and rising organic growth suggest that customer demand for consumables and services is firming, even as capital equipment purchases remain uneven. The quarter also carried an unusual GAAP wrinkle: a large non-cash intangible impairment charge tied to an older intellectual property agreement. For investors, the report highlights both improving end-market momentum and the accounting noise that can obscure underlying operating progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Repligen reported total revenue of $209.31 million, a 10.9% increase from $188.81 million a year earlier and modestly above the consensus estimate of about $206.75 million. Organic growth, which excludes acquisitions, divestitures, and foreign exchange, was 12.5%.
Adjusted (non-GAAP) diluted EPS came in at $0.53, topping the FactSet consensus of $0.46 by roughly 14.6%. Adjusted operating income rose 24% year over year to $33 million, and adjusted operating margin expanded 170 basis points to 15.9%. Adjusted EBITDA reached approximately $43.8 million, a 20.9% margin.
On a GAAP basis, results were weighed down by a $41 million non-cash intangible asset impairment charge related to an intellectual property license agreement. This contributed to a reported net loss of $38.4 million, or $0.68 per diluted share, versus net income of $14.9 million, or $0.26 per share, in the prior-year quarter.
Management also raised its full-year 2026 outlook, reflecting strength across the portfolio and the October 6 acquisition of BioLife. Revenue guidance was increased to a range of $844 million to $852 million, with BioLife expected to contribute roughly $24 million in the fourth quarter.
Market Reaction and Investor Sentiment
Investor response to the results appeared mixed. The company delivered a clear earnings beat on adjusted metrics and raised full-year guidance, which typically supports positive sentiment. However, the headline GAAP loss, driven by the sizable intangible impairment, introduced a layer of caution. Sentiment heading into the print had been constructive as bioprocessing demand gradually improved, and management's commentary about record capital equipment orders and strong China growth reinforced the narrative of a recovering end market. At the same time, the filtration segment's 11% decline, partly reflecting an anticipated headwind plus equipment delivery timing, remained a point of focus. Overall, the market's interpretation centered on the durability of consumables demand and the pace of capital equipment recovery rather than the one-time accounting charge.
Forward Outlook and Key Factors to Monitor
Following this report, investors are likely to focus on several forward-looking themes. First, guidance execution will matter: management now expects full-year revenue between $844 million and $852 million, with organic growth of 12% to 13%. The BioLife integration and its expected fourth-quarter contribution will be an early test of the company's cell therapy expansion strategy.
Second, the capital equipment cycle deserves close attention. Although equipment revenue declined in the quarter as deliveries shifted into 2027, orders grew by mid-teens and reached their highest quarterly level in five years. How quickly that backlog converts into recognized revenue will shape near-term growth visibility.
Third, margin trends remain important. Management indicated that the third quarter was expected to mark the low point for gross margin in 2026, and investors will watch whether product mix, pricing, and volume leverage support continued adjusted operating margin expansion.
Finally, regional dynamics, particularly China's greater than 40% growth, and the progression of consumables and services demand will be key indicators of underlying bioprocessing health as the industry continues its gradual recovery. From what I see, tracking these elements with tools like Tickeron’s AI Daily Buy/Sell Signals can help stay on top of shifting conditions.
Using Tickeron AI Tools in My Research
In my regular analysis of companies like RGEN, I rely on Tickeron’s AI Trading Bots to simulate strategies and test scenarios across different market conditions. This approach gives me a clearer view of potential outcomes without replacing my own judgment, and it has become a practical part of evaluating earnings reports and guidance updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RGEN's Indicator enters downward trend
The Aroon Indicator for RGEN entered a downward trend on September 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator formed such a pattern. In 181 of the 211 cases the stock moved lower. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 18 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 38 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RGEN as a result. In 66 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
RGEN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.814) is normal, around the industry mean (4.950). RGEN's P/E Ratio (243.473) is considerably higher than the industry average of (37.710). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biologic drugs
Industry PharmaceuticalsOther
Advertisement